A new report assesses the viability of new healthcare expansion options with Medicaid insurers.
Mona Shah
If Medicaid managed care plans offer coverage to more people and in more places, it could help protect consumers from higher healthcare costs, according to a new report.
The number of insurers participating in ACA individual insurance marketplaces has decreased over time, reveals a new report from the Urban Institute, with support from the Robert Wood Johnson Foundation (RWJF). Fewer insurers often leads to higher premiums for enrollees.
Related: The Future of the ACA
“This study looks at the possibility of convincing more Medicaid insurers to participate in the marketplaces and the impact that would have on lowering marketplace premiums,” says Mona Shah, senior program officer at RWJF. “Some Medicaid insurers have found that participation in the marketplace have expanded their footprints to new states and markets.”
Key findings include:
Generally, interviewees were in favor of Medicaid buy-in proposals, according to Shah. “These plans could allow Medicaid beneficiaries to retain continuous coverage year-round who may otherwise come on and off insurer’s Medicaid plans, as individuals’ incomes rise and fall,” she says.
Related: Top Medicaid Trends in 2019
The findings suggest that the closer Medicaid buy-in proposals hew to Medicaid program rules, the more likely that Medicaid insurers would participate in such programs, according to Shah.
There are three top reasons Medicaid insurers do not sell plans in ACA marketplaces, according to Shah:
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More